CRONOS GROUP INC (CRON.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:CRON - CA22717L1013 - Common Stock
3.76 CAD
+0.01 (+0.27%)
We assign a fundamental rating of 4 out of 10 to CRON. CRON was compared to 30 industry peers in the Pharmaceuticals industry. CRON has a great financial health rating, but its profitability evaluates not so good. CRON is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CRON had positive earnings in the past year.
In the past year CRON had a positive cash flow from operations.
CRON had negative earnings in 4 of the past 5 years.
In the past 5 years CRON reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of CRON (3.06%) is better than 76.47% of its industry peers.
With a decent Return On Equity value of 3.33%, CRON is doing good in the industry, outperforming 76.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.06% | ||
| ROE | 3.33% | ||
| ROIC | N/A |
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CRON has a better Profit Margin (27.27%) than 91.18% of its industry peers.
CRON's Profit Margin has declined in the last couple of years.
CRON has a Gross Margin of 43.35%. This is comparable to the rest of the industry: CRON outperforms 55.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 27.27% | ||
| GM | 43.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRON has more shares outstanding
Compared to 5 years ago, CRON has more shares outstanding
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CRON has an Altman-Z score of 8.07. This indicates that CRON is financially healthy and has little risk of bankruptcy at the moment.
CRON has a Altman-Z score of 8.07. This is amongst the best in the industry. CRON outperforms 97.06% of its industry peers.
There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.07 |
ROIC/WACCN/A
WACC8.4%
2.3 Liquidity
A Current Ratio of 22.45 indicates that CRON has no problem at all paying its short term obligations.
CRON's Current ratio of 22.45 is amongst the best of the industry. CRON outperforms 100.00% of its industry peers.
A Quick Ratio of 21.28 indicates that CRON has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 21.28, CRON belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 22.45 | ||
| Quick Ratio | 21.28 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 283.33% over the past year.
CRON shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -50.78% yearly.
Looking at the last year, CRON shows a quite strong growth in Revenue. The Revenue has grown by 19.00% in the last year.
The Revenue has been growing by 37.71% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)283.33%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
Revenue 1Y (TTM)19%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%6.06%
3.2 Future
CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.14% yearly.
CRON is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.39% yearly.
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue Next Year11.03%
Revenue Next 2Y20.49%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 25.07 indicates a quite expensive valuation of CRON.
Based on the Price/Earnings ratio, CRON is valued a bit cheaper than the industry average as 67.65% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of CRON to the average of the S&P500 Index (26.92), we can say CRON is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 38.49, the valuation of CRON can be described as expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as CRON.
CRON's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.07 | ||
| Fwd PE | 38.49 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
5. Dividend
5.1 Amount
CRON does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:CRON (12/24/2025, 7:00:00 PM)
3.76
+0.01 (+0.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.95%
Inst Owner ChangeN/A
Ins Owners6.24%
Ins Owner ChangeN/A
Market Cap1.44B
Revenue(TTM)132.36M
Net Income(TTM)36.10M
Analysts82.86
Price Target5.1 (35.64%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.4%
Min Revenue beat(2)-4.49%
Max Revenue beat(2)-0.31%
Revenue beat(4)0
Avg Revenue beat(4)-5%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)-0.21%
Revenue beat(8)3
Avg Revenue beat(8)-1.43%
Revenue beat(12)4
Avg Revenue beat(12)-1.97%
Revenue beat(16)6
Avg Revenue beat(16)-3.29%
PT rev (1m)0%
PT rev (3m)112.77%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-8.28%
Revenue NQ rev (3m)-8.28%
Revenue NY rev (1m)-1.71%
Revenue NY rev (3m)-1.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.07 | ||
| Fwd PE | 38.49 | ||
| P/S | 7.95 | ||
| P/FCF | N/A | ||
| P/OCF | 48.37 | ||
| P/B | 0.97 | ||
| P/tB | 1.04 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.15
EY3.99%
EPS(NY)0.1
Fwd EY2.6%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.08
OCFY2.07%
SpS0.47
BVpS3.87
TBVpS3.6
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.61
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.06% | ||
| ROE | 3.33% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 27.27% | ||
| GM | 43.35% | ||
| FCFM | N/A |
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 209.86% | ||
| Cap/Sales | 20.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 22.45 | ||
| Quick Ratio | 21.28 | ||
| Altman-Z | 8.07 |
F-Score6
WACC8.4%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)283.33%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)19%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%6.06%
Revenue Next Year11.03%
Revenue Next 2Y20.49%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
EBIT growth 1Y70.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year119.92%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y93.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y125.89%
OCF growth 3YN/A
OCF growth 5YN/A
CRONOS GROUP INC / CRON.CA FAQ
What is the fundamental rating for CRON stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRON.CA.
What is the valuation status for CRON stock?
ChartMill assigns a valuation rating of 1 / 10 to CRONOS GROUP INC (CRON.CA). This can be considered as Overvalued.
How profitable is CRONOS GROUP INC (CRON.CA) stock?
CRONOS GROUP INC (CRON.CA) has a profitability rating of 3 / 10.
What is the expected EPS growth for CRONOS GROUP INC (CRON.CA) stock?
The Earnings per Share (EPS) of CRONOS GROUP INC (CRON.CA) is expected to decline by -115.3% in the next year.